Human intrabony defect regeneration with rhFGF-2 and hyaluronic acid - a randomized controlled clinical trial.
OBJECTIVE
The goal of this study was to evaluate if a biological hydrogel of recombinant human Fibroblast Growth Factor type 2 (rhFGF-2) in a hyaluronic acid (HA) carrier applied in periodontal intrabony defects would enhance the clinical parameters of regeneration of the periodontal attachment apparatus


METHODS
Thirty adult patients were evaluated. Two intrabony defects present in contra-lateral quadrants in each patient were randomly allocated for each of the treatment methods employed. Control group (n = 30) were treated by open debridement with the papilla preservation flaps, while the test group (n = 30) also received a topical application of rhFGF-2/HA in the intrabony defect. The parameters evaluated, at baseline and after one year, were, were probing depth (PD), gingival recession (REC), probing attachment level (PAL) and probing bone level (PBL). The primary outcome measures was PAL gain


RESULTS
Test sites exhibited significantly more PD reduction (5.5 versus 2.9 mm), PAL gains (4.8 versus 2.2 mm) and shallower residual PD (4.2 versus 6.6 mm) than controls. Moreover, residual PD smaller than 5 mm (100 versus 0%) and PAL gain > 4 mm (60 versus 20%) was significantly more frequent in the test group


CONCLUSIONS
Application of rhFGF-2/HA significantly improved clinical parameters of periodontal wound healing one year after treatment.
Department of Periodontology, Federal Fluminense University, Dental School, Niteroi, Rio de Janeiro, Brazil.
Ronaldo Barcellos
RB
de Santana
Department of Periodontology, Federal Fluminense University, Dental School, Niteroi, Rio de Janeiro, Brazil.
Carolina Miller Mattos
CM
de Santana
D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000188:drug therapy*; D000539:Alveolar Process / Q000187:drug effects; D001861:Bone Regeneration / Q000187:drug effects*; D055113:Chronic Periodontitis / Q000188:drug therapy; D003646:Debridement / Q000379:methods; D004337:Drug Carriers; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005889:Gingival Recession / Q000188:drug therapy; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000188:drug therapy; D010514:Periodontal Pocket / Q000188:drug therapy; D011446:Prospective Studies; D019252:Radiography, Dental, Digital / Q000379:methods; D011994:Recombinant Proteins; D013524:Surgical Flaps / Q000601:surgery; D016896:Treatment Outcome
D004337:Drug Carriers; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D006820:Hyaluronic Acid
periodontal regeneration; periodontitis; rhFGF-2